EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSLLEG00000012412
Gene Symbol: CACNA1C
1 View Cross-references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSLLEG00000029563
Gene Symbol: CACNA1D
1 View Cross-references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSLLEG00000030299
Gene Symbol: CACNA1E
1 View Cross-references
294 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSLLEG00000009525
Gene Symbol: CACNA1F
1 View Cross-references
179 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSLLEG00000017691
Gene Symbol: CACNA1H
1 View Cross-references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSLLEG00000004506
Gene Symbol: CACNA1S
1 View Cross-references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cannabinoid Receptor 1

Ensembl ID : ENSLLEG00000020460
Gene Symbol: CNR1
1 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cannabinoid Receptor 2

Ensembl ID : ENSLLEG00000012659
Gene Symbol: CNR2
1 View Cross-references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 1

Ensembl ID : ENSLLEG00000025201
Gene Symbol: CA1
1 View Cross-references
285 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 12

Ensembl ID : ENSLLEG00000004636
Gene Symbol: CA12
1 View Cross-references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 13

Ensembl ID : ENSLLEG00000025270
Gene Symbol: CA13
1 View Cross-references
288 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Carbonic Anhydrase 2

Ensembl ID : ENSLLEG00000025011
Gene Symbol: CA2
1 View Cross-references
285 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).